Welcome to Dragonfly Biosciences, Europe’s leading premium retailer of Cannabidiol (CBD).

A research-fuelled and community-minded company, Dragonfly controls the process from seed to sale, guaranteeing the highest and most consistent product quality. We work strictly within the frontiers of current legislation and operate with total transparency, keeping our fields, processing facility, laboratories and products open to consumers.

Currently offering a range of CBD health and lifestyle products, Dragonfly aims to expand its business and product range in line with legal changes in Europe.

As demand grows for CBD health supplements, we will continue to be the go-to producer and supplier of Cannabidiol for both businesses and consumers.

Why Choose Us?


Why Choose Us?


Guaranteed accurate concentration (%) of CBD


Produced under stringent control and tested by independent, accredited labs


Organically certified product


Customer service that can help you before, during and after the purchase

All our products are tested in third-party laboratories, as well as our own to ensure consistency and quality across the board. Dragonfly works under Good Manufacturing Practices (GMP). Our product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a, CBN and CBG. We guarantee that our products are 100% organic. Click here to read more…

Our Team
The Team


The Team


President & Co-Founder

Radost is a Sofia-based entrepreneur and experienced businesswoman. Equipped with a law degree, she spent her early years as head of the Legal Department at Sofia Municipality, responsible for all large-scale urban development, architecture, and infrastructure-focused projects. She has since dedicated her career to developing a series of solar farms, as well her own highly successful TV production company.


Chairman & Acting CEO

Chris is a serial entrepreneur and investor. With experience in both media and health-related industries, he is now an acting CEO; previously involved in Wellbeing Network, where he also served as a CEO. He founded Chello Zone Holdings (also known as Zone Vision Networks) in 1991 and served its President. As President of Chello Zone, Chris developed and expanded Zone Vision Networks worldwide.


Chief Financial Officer

Regan is a Chartered Accountant by trade with over 20 years experience in the media industry. Bringing a breadth of experience, he has spent stints at NBCUniversal International as VP Finance, AMC Networks International as Chief Financial Officer and has held various senior finance roles at the BBC.


Chief Operating Officer

Hannah spent her early years as an analyst at The RSA Group and then later at Goodlord. After topping the Management Tripos at Kings College London, she studied for a Masters in Management at the London School of Economics. Promoted from Business Development Associate to the Head of Business Development within a year, she is an asset to the company.



Co-Founder & Board Member

Mark is a real media mogul after 30 years in the industry. Initially at Lloyds of London, he then became one of the original team members of Henson International Television – the creators of The Muppet Show. After a prosperous stint in TV and film production, he put together a group that raised US$250m to acquire the International Library Rights to titles of the Hallmark Channel, which was then acquired by NBC Universal in 2007. He subsequently has multiple equity investments in digital media.


Investor & Board Member

Paul has more than 25 years leadership experience in the pharmaceutical industry. After spending 14 years at GlaxoSmithKline (GSK), including a stint as the General Manager of Europe, Paul later became the Executive Vice President of Worldwide Commercial Operations at Gilead Sciences Inc. He also spent four years working at Arthur Anderson and is now the board director of several biotech companies, as well as being a Fellow of the UK Chartered Institute of Management Accountants.


Advisory Board Member

Olav is an international pharmaceutical executive with particular expertise in clinical development, out-licensing, commercialisation and the marketing of new therapeutics. Currently the Chief Executive Officer of ReNeuron PLC., Olav holds an impressive track record as the previous CEO at Clavis Pharma ASA, a listed biotechnology company; the head of the UK commercial operations at Novartis; and the head of the global bio-logistics franchise at UCB Pharma. He has a Bachelor of Business Administration from Hofstra University, USA, and an MBA from the IESE Business School.


Advisory Board Member

Dominik is a seasoned finance operative and media entrepreneur. Based in Poland, his career includes stints as Chief Investment Officer at Kulczyk Investments and Chief Executive Officer at Cyfrowy Polsat SA, CPS:WSE. He also ran his own television company – Studio Meg – and holds a Master’s degree from the Department of Environmental Studies and Environmental Protection Faculty at the Wroclaw Technical University.


Advisory Board Member

Dermot is a chartered accountant and global executive with over 20 years’ experience leading complex, high-growth, multi-national organizations. He has been Chief Executive Officer of Zone Vision Networks Ltd. since January 2002 and played a key role in building and selling the (US$1million) company. Fabled for his operational control, commercial creativity and strategic planning, Dermott has helped to grow brands such as CNBC, Discovery, Animal Planet, Food Network, CBS, Extreme Sports, Outdoor Channel, MGM and AMC.


Advisory Board Member

Alex boasts a wealth of experience with the Virgin Group. Currently the team principal of the Virgin Racing Formula E, he has been both director of Virgin Management and CEO for Virgin Galactic, playing a pivotal role alongside Richard Branson in leading the company towards its first commercial space flight – now only two years away. Alex is a trained Aviation pilot and holds additional experience in property development.


Advisory Board Member

Ewa is one of the most recognised authorities in the Polish Hemp business. After studying Cannabis Sativa L. in depth back in 2004, she opened a General Hemp Marketing Company. She is a distributor of several international hemp brands and has two of her own: Dobre Konopie and Konopie W Kichini. Ewa holds an MA in Biology & Animal Sciences from the University of Agriculture, Krakow.


Advisory Board Member

Sayed is an investor and senior consultant at MYAH capital, a strategic consultancy firm he founded to assist businesses entering new markets. He has worked in a range of project management and accountancy roles at Sainsbury’s, TK Maxx and WorldCom. He also holds experience in launching new brands such as Beats by Dr Dre in the UK.


Advisory Board Member

Saoirse brings 15 years of cannabinoid wisdom to the Dragonfly board. Currently serving as Associate Professor at the University of Nottingham, her research is centred in on the endocannabinoid system, with a particular focus on the role it plays in diabetes and obesity. Since 2016, she has been named Young Investigator of the Year by the International Cannabinoid Research Society and acted as a source of expertise for numerous BBC documentaries. A seasoned academic, she will keep us at the cutting edge of new research findings.


Advisory Board Member

Gary is a professor and Director of Pharmacology and Therapeutics at the University of Reading. He is a regular author in the British Journal of Pharmacology, as well as being a member of its editorial board. From papers on epilepsy to the central nervous system, Gary has been researching cannabinoids for the past decade, with a particular interest in how they interact with the brain.


Advisory Board Member

Brian is a consultant in respiratory medicine, specialising in allergies and airway diseases. He is fully active in clinical research and has published in highly regarded peer-reviewed journals, edited numerous books and written chapters on Asthma and Chronic Pulmonary Disease (COPD). He is one of the founders of Queen Anne Street Medical Centre.


Advisory Board Member

Julian has worked for the Bulgarian Academy of Sciences for nearly 20 years, developing an in-depth knowledge of cannabis in the process. One of the most recognised authorities on pharmaceuticals in Bulgaria, he has written two books – including Cannabis: Science and Politics – and is currently working on a paper exploring the synthesis and biomedical testing of a new class of synthetic cannabinoids.

Our Team

What is CBD?

Cannabidiol, or CBD, is just one of the 113 cannabinoids naturally found in the Cannabis sativa plant. In contrast to the more commonly known cannabinoid, THC, it has no psychoactive properties, is completely legal, and when isolated, can have a multitude of health benefits.

More information here 

Extraction Process

After harvesting, our three stage state of the art extraction process is used to produce the highest quality CBD. We use an ethanol method as it both maximises product flexibility and better suits the scale of our operation.

Oil extraction and other product development is undertaken by industry experts in the Pharmaceutical division of Dragonfly. All our products are then processed and packaged in a GMP certified facility.


Our Product Range

We work with independent labs across the country to test our PCR hemp oil. Accurately testing the product is of utmost importance to ensure our customers the highest quality of our product. No harmful solvents are used in the processing of our products.


We are a proud member of the Cannabis Trades Association

full member 2018